Home
Clene, Inc.

Clene, Inc. Market Share Analysis for February 2026

Health > Biotechnology and Pharmaceuticals

Domainclene.com

Year Founded2013

Employees51 - 200

Annual Revenue< $1M

Clene, Inc.

Clene, Inc. (including company regionals)

clene.com

See more website traffic and engagement information

Total visits to Clene, Inc.'s top domains

Understand Clene, Inc. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

clene.com3.9K

See more with Sales Intelligence

Avg. visit duration in Clene, Inc.'s top domains

Analyze Clene, Inc. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

clene.com00:00:30

See more with Sales Intelligence

Avg. pageviews on Clene, Inc.'s top domains

See how Clene, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

clene.com1.79

See more with Sales Intelligence

Clene, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Clene, Inc.

These are the website technologies, by industry, used by Clene, Inc. top domains

Payment & Currencies (10)

Cart Functionality

Widget (6)

Twemoji

Advertising (5)

DoubleClick

eCommerce (5)

WooCommerce

More Technologies

11

See all

News & Signals from Clene, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsClene, Inc. attends event Benchmark 14th Annual Discovery One-on-One Investor Conference.Clene to participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference.

NewsClene, Inc. attended event Maxim Growth Summit on Oct 22nd '25.Clene (Nasdaq: CLNN) said management will participate in a panel discussion at the Maxim Growth Summit and will host 1x1 investor meetings on October 22, 2025 in New York City.

NewsClene, Inc. attends event 41st Congress of.Clene (NASDAQ: CLNN) announced presentation of combined REPAIR-MS trial results at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Barcelona, showing CNM-Au8 significantly improved brain NAD+/NADH ratios, a key marker of energetic capacity, across relapsing and non-active progressive MS patients.